Rezolute的低血糖治疗 获得了FDA的孤儿药物地位 帮助罕见的病人 Rezolute's low blood sugar treatment gets FDA orphan drug status, aiding rare disease patients.

Rezolute是一家生物技术公司,因低血糖治疗而获得林业发展局指定为孤儿的药物 -- -- eodotug,针对的是引发过度胰岛素活动的肿瘤造成的一种罕见情况。 Rezolute, a biotech firm, received FDA's orphan-drug designation for its low blood sugar treatment, ersodetug, targeting a rare condition caused by tumors that trigger excessive insulin activity. 这一指定提供了7年的市场排他性和更快的批准途径,目的是鼓励治疗罕见疾病。 This designation offers seven years of market exclusivity and faster approval pathways, aiming to encourage treatments for rare diseases. REZLUTE计划于2025年开始对Esodotug进行第三阶段试验。 Rezolute plans to start a Phase 3 trial for ersodetug in 2025.